公开(公告)号：US20160367564A1

公开(公告)日：2016-12-22

申请号：US15100494

申请日：2014-12-02

申请人： IOMET PHARMA LTD

发明人： Phillip Martin Cowley ,  Alan Wise ,  Margaret Huggett

IPC分类号： A61K31/551 ,  C07D401/04 ,  A61K31/454 ,  C07D401/14 ,  C07D471/04 ,  A61K31/4545 ,  A61K31/4439 ,  C07D413/14 ,  C07D409/14 ,  A61K31/444 ,  C07D405/14 ,  A61K31/4725 ,  C07D209/40 ,  A61K31/496 ,  A61K31/498 ,  C07D403/04 ,  A61K31/404 ,  C07D471/10 ,  A61K31/435 ,  C07D401/06 ,  C07D209/20 ,  C07D403/06 ,  A61K31/55 ,  A61K31/506 ,  C07D487/04 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/497 ,  C07D513/04 ,  A61K45/06

CPC分类号： A61K31/551 ,  A61K31/404 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D209/20 ,  C07D209/34 ,  C07D209/40 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D513/04

摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X2, X4, X10, and X11 may be the same or different and each is independently selected from C and N; X1, X3, X5, X6, X7, X8, and X9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X4 with the carbon atoms either side of X2 are single bonds, and are only present when X2 is absent, X3 is absent and X4 is C, and when these bonds are present the ring carbons on each side of X2 are not directly bonded to each other; each R1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R1 groups present is such that the valency of X1 is maintained; each R12, R13, R13′, R14, R15 and R15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R16 groups present is such that the valency of X2 is maintained; each R17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R17 groups present is such that the valency of X3 is maintained; each R2, R3, R4, and R5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X6, X7, X8, and X9 are maintained; each R7, R8 and R9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X10, X11, and X5 are maintained; and R6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C1-C6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.

公开(公告)号：US09931347B2

公开(公告)日：2018-04-03

申请号：US15100494

申请日：2014-12-02

申请人： IOmet Pharma Ltd.

发明人： Phillip Martin Cowley ,  Alan Wise ,  Margaret Huggett

IPC分类号： A61K31/551 ,  A61K31/404 ,  C07D401/04 ,  C07D403/12 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D209/34 ,  C07D209/40 ,  C07D513/04 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D209/20 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/10

CPC分类号： A61K31/551 ,  A61K31/404 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D209/20 ,  C07D209/34 ,  C07D209/40 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D513/04

摘要： Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X2, X4, X10, and X11 may be the same or different and each is independently selected from C and N; X1, X3, X5, X6, X7, X8, and X9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X4 with the carbon atoms either side of X2 are single bonds, and are only present when X2 is absent, X3 is absent and X4 is C, and when these bonds are present the ring carbons on each side of X2 are not directly bonded to each other; each R1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R1 groups present is such that the valency of X1 is maintained; each R12, R13, R13′, R14, R15 and R15′ may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R16 groups present is such that the valency of X2 is maintained; each R17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R17 groups present is such that the valency of X3 is maintained; each R2, R3, R4, and R5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X6, X7, X8, and X9 are maintained; each R7, R8 and R9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X10, X11, and X5 are maintained; and R6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C1-C6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.

公开(公告)号：US20160120863A1

公开(公告)日：2016-05-05

申请号：US14893513

申请日：2014-05-22

申请人： IOMET PHARMA LTD.

发明人： Phillip Martin Cowley ,  Alan Wise ,  Thomas James Brown ,  Matthew Isherwood ,  Anjan Chakrabarti

IPC分类号： A61K31/496 ,  G01N33/50 ,  A61K45/06 ,  C07D471/04 ,  A61K31/5377

CPC分类号： A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00 ,  G01N33/502 ,  G01N2333/705 ,  G01N2500/04 ,  G01N2500/10 ,  Y02A50/385 ,  Y02A50/414 ,  Y02A50/423

摘要： Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula: wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each X may be the same or different and is independently selected from C, N, O and S; R1 and R5 may be present or absent and may be the same or different and are each selected from H and a substituted or unsubstituted organic group; Z completes a ring with each X, each ring comprising from 3 to 8 ring atoms including the X, A, and Z, each ring atom being independently selected from C, N, O and S, and each ring atom being unsubstituted or independently substituted with H or a substituted or unsubstituted organic group; and wherein the bonds between all of the atoms in the rings including the X, A, and Z may independently be single bonds or double bonds, provided that when X or a ring atom is O or S the bonds to X are single bonds.

摘要翻译： 本发明提供一种用于医药的SLC2A I类转运蛋白抑制剂化合物，该化合物包含下式：其中A和Z可以相同或不同，并且各自独立地选自C，N，O和S; 每个X可以相同或不同，并且独立地选自C，N，O和S; R 1和R 5可以存在或不存在，并且可以相同或不同，并且各自选自H和取代或未取代的有机基团; Z与每个X完成一个环，每个环包含3至8个环原子，包括X，A和Z，每个环原子独立地选自C，N，O和S，每个环原子是未取代或独立取代的 与H或取代或未取代的有机基团; 并且其中包括X，A和Z的环中所有原子之间的键可以独立地为单键或双键，条件是当X或环原子为O或S时，与X的键为单键。